Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A Sahraian

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Minerva Medica|September 7, 2013
A polymorphism in the resistin gene promoter and the risk of multiple sclerosisA Hossein-Nezhad, F N Varzaneh, K Mirzaei, et al.
Acta Neurologica Scandinavica|May 22, 2007
Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating eventH Pakdaman, M A Sahraian, A Fallah, et al.
Acta Neurologica Scandinavica|March 16, 2018
Smoking and worsening disability in multiple sclerosis: A meta-analysisP Heydarpour, A Manouchehrinia, O Beiki, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 21, 2009
Multiple sclerosis and neurofibromatosis type 1: report of seven patients from IranM Etemadifar, F Fatehi, M A Sahraian, et al.
Genetics and Molecular Research : GMR|September 26, 2013
Mitochondrial and nuclear genes as the cause of complex I deficiencyA R Rezaee, A Azadi, M Houshmand, et al.
European Journal of Neurology|July 21, 2011
Serum and CSF PDGF-AA and FGF-2 in relapsing-remitting multiple sclerosis: a case-control studyM H Harirchian, A H Tekieh, A Modabbernia, et al.
Journal of Molecular Neuroscience : MN|April 1, 2015
Dominant and Protective Role of the CYTH4 Primate-Specific GTTT-Repeat Longer Alleles Against NeurodegenerationM Rezazadeh, J Gharesouran, A Movafagh, et al.
Clinical and Experimental Immunology|December 2, 2017
A systems medicine approach reveals disordered immune system and lipid metabolism in multiple sclerosis patientsM Pazhouhandeh, M-A Sahraian, S D Siadat, et al.
Acta Neurologica Belgica|September 15, 2023
Comparing infusion-related reactions of the first full dose (600 mg) biosimilar ocrelizumab administration with the standard divided protocol in multiple sclerosis patients: a randomized controlled trial studyNaghmeh Abbasi Kasbi, F Ghadiri, M A Sahraian, et al.
European Journal of Neurology|April 22, 2019
Burden of neurodegenerative diseases in the Eastern Mediterranean Region, 1990-2016: findings from the Global Burden of Disease Study 2016S-M Fereshtehnejad, K Vosoughi, P Heydarpour, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Minerva Medica|September 7, 2013
A polymorphism in the resistin gene promoter and the risk of multiple sclerosisA Hossein-Nezhad, F N Varzaneh, K Mirzaei, et al.
Acta Neurologica Scandinavica|May 22, 2007
Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating eventH Pakdaman, M A Sahraian, A Fallah, et al.
Acta Neurologica Scandinavica|March 16, 2018
Smoking and worsening disability in multiple sclerosis: A meta-analysisP Heydarpour, A Manouchehrinia, O Beiki, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 21, 2009
Multiple sclerosis and neurofibromatosis type 1: report of seven patients from IranM Etemadifar, F Fatehi, M A Sahraian, et al.
Genetics and Molecular Research : GMR|September 26, 2013
Mitochondrial and nuclear genes as the cause of complex I deficiencyA R Rezaee, A Azadi, M Houshmand, et al.
European Journal of Neurology|July 21, 2011
Serum and CSF PDGF-AA and FGF-2 in relapsing-remitting multiple sclerosis: a case-control studyM H Harirchian, A H Tekieh, A Modabbernia, et al.
Journal of Molecular Neuroscience : MN|April 1, 2015
Dominant and Protective Role of the CYTH4 Primate-Specific GTTT-Repeat Longer Alleles Against NeurodegenerationM Rezazadeh, J Gharesouran, A Movafagh, et al.
Clinical and Experimental Immunology|December 2, 2017
A systems medicine approach reveals disordered immune system and lipid metabolism in multiple sclerosis patientsM Pazhouhandeh, M-A Sahraian, S D Siadat, et al.
Acta Neurologica Belgica|September 15, 2023
Comparing infusion-related reactions of the first full dose (600 mg) biosimilar ocrelizumab administration with the standard divided protocol in multiple sclerosis patients: a randomized controlled trial studyNaghmeh Abbasi Kasbi, F Ghadiri, M A Sahraian, et al.
European Journal of Neurology|April 22, 2019
Burden of neurodegenerative diseases in the Eastern Mediterranean Region, 1990-2016: findings from the Global Burden of Disease Study 2016S-M Fereshtehnejad, K Vosoughi, P Heydarpour, et al.
Pageof 3